Arvinas, Pfizer Partner To Pursue Best-In-Class Breast Cancer Strategy

Protein Degradation Specialist Gets $1bn Up Front

 
• By Mandy Jackson
  
Stand out from the crowd
Multiple SERDs are ahead of ARV-471 but Pfizer and Arvinas believe they have a best-in-class estrogen receptor degrader • Source: Alamy
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Deals

More from Business